Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that its late-breaking abstract for voclosporin has been accepted for oral presentation at the National Kidney Foundation (NKF) 2017 Spring Clinical Meetings taking place April 18-22, 2017 in Orlando, FL. The oral presentation, titled “Treatment of Active Lupus Nephritis with Voclosporin: 48 Week Data from the AURA-LV Study,” will be made by lead author Dr. Samir Parikh, a clinical investigator for the study and Assistant Professor, Clinical Nephrology at the Ohio State University, on Thursday, April 20, 2017 from 4:00 p.m. – 5:30 p.m. ET.
A corresponding Late Breaking poster presentation of the 48-week AURA-LV study data will also be presented at the NKF 2017 Scientific Clinical Meetings.
“We’re pleased that the AURA-LV 48-week data have been accepted for a late-breaking oral presentation and look forward to sharing these important results with the nephrology scientific and medical communities,” said Richard M. Glickman, Aurinia’s Chief Executive Officer.
Shares of Aurinia closed today at $5.36, up $0.55 or 11.43%. AUPH has a 1-year high of $6 and a 1-year low of $1.74. The stock’s 50-day moving average is $3.32 and its 200-day moving average is $2.94.
On the ratings front, Aurinia has been the subject of a number of recent research reports. In a report issued on March 1, FBR analyst Vernon Bernardino reiterated a Buy rating on AUPH. Separately, H.C. Wainwright’s Ed Arce reiterated a Buy rating on the stock and has a price target of $8.00.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Ed Arce have a yearly average loss of 14.4% and a return of 24.1% respectively. Bernardino has a success rate of 27% and is ranked #4438 out of 4513 analysts, while Arce has a success rate of 50% and is ranked #164.
Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules for the treatment of lupus nephritis.